Every public signal F4 has attached to this firm, with sources and cross-entity links.
Essay
Published "The State of Frontier Neuroscience: This is the century of the brain" — a comprehensive thesis essay on why neuro is investable now, covering neurotech, programmable medicines, psychedelics, computational biology, brain foundation models, and human enhancement.
Published "Digital Addiction: The Investment Landscape + What Wins Now" — an investment thesis essay analyzing the digital addiction market, covering physical products, software-based well-being tools, and screen-free products for kids, with a focus on app blockers and hybrid consumer-institutional models.
PsyMed Ventures and KdT Ventures hosted the 2nd annual Future Neuro Founders Program with 400+ founders from 190 universities, covering how to turn neuro ideas into companies.
Launched Fund II with a focus on frontier neuroscience, brain health, mental health, and human augmentation. Made three investments so far. Fund I performing in top decile for its vintage.
Delix Therapeutics reported positive Phase 1b results: lead non-hallucinogenic 5-MeO-DMT analog reduced depression symptoms by ~50% within a week, with benefits lasting weeks. FDA cleared Phase II design including at-home administration.